A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label and two-part study to evaluate the safety, tolerability,
pharmacokinetics and efficacy of FDA022-BB05 in participants with advanced/metastatic solid
malignant tumors.